Gen Probe (GPRO) Discloses Postponed FDA Panel Review of Progensa
Tweet
Share
E-mailGet Alerts GPRO Hot Sheet
Join SI Premium – FREE
According to a Form 8-K just filed, Gen Probe (Nasdaq: GPRO) has said its FDA panel review of Progensa has been postponed. The FDA has said it will take added time to review and respond. Gen Probe sees the panel review during the first quarter of 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Home Depot expands executive roles, grants $500K in restricted stock
- Sigma Lithium resumes full operations after signing TAC agreement
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
